Corcept Therapeutics (CORT) Expected to Post Quarterly Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) is expected to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.0123 per share and revenue of $219.1260 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. During the same period in the prior year, the business posted $0.17 earnings per share. Corcept Therapeutics’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $95.36 on Monday. The firm’s fifty day moving average price is $80.40 and its two-hundred day moving average price is $54.61. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $97.63. The firm has a market capitalization of $10.24 billion, a P/E ratio of 272.46 and a beta of 0.47.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 75,000 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total value of $4,919,250.00. Following the transaction, the insider directly owned 8,977 shares of the company’s stock, valued at $588,801.43. This represents a 89.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Wilson sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the sale, the director owned 1,094,543 shares of the company’s stock, valued at $91,065,977.60. This trade represents a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,000 shares of company stock worth $22,088,050 in the last 90 days. Corporate insiders own 20.70% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several hedge funds have recently added to or reduced their stakes in CORT. State Street Corp grew its holdings in Corcept Therapeutics by 0.5% in the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after buying an additional 15,656 shares in the last quarter. Morgan Stanley boosted its position in shares of Corcept Therapeutics by 34.1% in the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after acquiring an additional 405,081 shares during the period. AQR Capital Management LLC boosted its position in shares of Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the period. Epoch Investment Partners Inc. grew its stake in shares of Corcept Therapeutics by 10.7% in the third quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock valued at $70,403,000 after acquiring an additional 81,700 shares in the last quarter. Finally, Invesco Ltd. grew its stake in shares of Corcept Therapeutics by 11.5% in the fourth quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock valued at $28,431,000 after acquiring an additional 84,413 shares in the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on CORT. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group boosted their price target on Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. HC Wainwright upped their price objective on Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.83.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.